MOUNTAIN VIEW, Calif.,
April 29, 2015 /PRNewswire/
-- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced
two management promotions. Dr. Edwin
S. Kamemoto has been promoted to the newly created position
of Executive Vice President, R&D and Quality. In this new
role, Dr. Kamemoto will be responsible for research and
development, regulatory affairs, clinical research,
pharmacovigilance, and the quality functions at Alexza. Dr.
Lori H. Takahashi has been
promoted to the newly created position of Vice President,
Pharmaceutical R&D and Quality. In this new role,
Dr. Takahashi will be responsible for product research and
development, toxicology, pharmacokinetics/ADME (PK/ADME),
analytical development, and day-to-day leadership of the quality
functions at Alexza.
- Edwin S. Kamemoto, PhD, has
served as Alexza's Senior Vice President, Regulatory Affairs since
2014. Dr. Kamemoto joined Alexza in 2006 as Associate
Director, Regulatory Affairs, and was promoted to Director,
Regulatory Affairs in 2007, to Senior Director, Regulatory Affairs
in 2008, to Executive Director, Regulatory Affairs in 2010, and to
Vice President, Regulatory Affairs in 2012. From 2004 to
2006, Dr. Kamemoto was a consultant for CATO Research, a contract
research organization. From 1995 to 2004, he held various
scientific and regulatory affairs managerial positions at Nektar
Therapeutics. He also held previous scientific-related
positions at Collagen Corporation/Celtrix Pharmaceuticals and
Glycomed. Dr. Kamemoto received a PhD in biochemistry from
UCLA, completed a postdoctoral
fellowship in the Department of Pharmacology at Stanford University, and received a BS
in chemistry and biology from
University of Hawaii.
- Lori H. Takahashi, PhD, has
served as Alexza's Executive Director, Non-Clinical R&D, where
she was in charge of product R&D, toxicology, PK/ADME, and
analytical development. Dr. Takahashi joined Alexza in 2005
as Senior Director, PK/ADME & Analytical Development.
Previous to Alexza, Dr. Takahashi was the Director of Drug
Metabolism at Gilead Sciences, Inc. from 2003 to 2004 and, prior to
that position, headed the PK/ADME group for Elan
Pharmaceuticals, Inc. from 2001 to 2003. She also served as a
Staff Scientist I, II, Senior Scientist and Research Fellow for the
Affymax Research Institute (wholly-owned subsidiary of Glaxo
Wellcome) from 1994 to 2001. Dr. Takahashi holds a PhD
in chemistry from Texas A&M
University and M and BS degrees in chemistry from
San Jose State University.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development, and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products are based on the Staccato® system, a hand-held
inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.
ADASUVE®, Alexza's first commercial product, is based
on the Staccato system and has been approved for sale by the
U.S. Food and Drug Administration, the European Commission,
and in eight Latin American countries. ADASUVE is currently
being marketed in thirteen EU member countries, the United States, and one country in Latin
America.
Teva Pharmaceuticals USA, Inc.,
a subsidiary of Teva Pharmaceutical Industries Ltd., is
Alexza's commercial partner for ADASUVE in the United States.
Grupo Ferrer Internacional SA is Alexza's commercial partner for
ADASUVE in Europe, Latin America and the Commonwealth of
Independent States countries.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc. For more
information, please visit www.alexza.com.
Logo -
http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/alexza-pharmaceuticals-announces-management-promotions-300074026.html
SOURCE Alexza Pharmaceuticals, Inc.